IGF-IR Polyclonal Antibody

    • Catalog No.:YT2282
    • Applications:IF;WB;IHC;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • IGF-IR
      • Fields:
      • >>EGFR tyrosine kinase inhibitor resistance;>>Endocrine resistance;>>MAPK signaling pathway;>>Ras signaling pathway;>>Rap1 signaling pathway;>>HIF-1 signaling pathway;>>FoxO signaling pathway;>>Oocyte meiosis;>>Autophagy - animal;>>Endocytosis;>>mTOR signaling pathway;>>PI3K-Akt signaling pathway;>>AMPK signaling pathway;>>Longevity regulating pathway;>>Longevity regulating pathway - multiple species;>>Focal adhesion;>>Adherens junction;>>Signaling pathways regulating pluripotency of stem cells;>>Long-term depression;>>Ovarian steroidogenesis;>>Progesterone-mediated oocyte maturation;>>Pathways in cancer;>>Transcriptional misregulation in cancer;>>Proteoglycans in cancer;>>Glioma;>>Prostate cancer;>>Melanoma;>>Breast cancer;>>Hepatocellular carcinoma
      • Gene Name:
      • IGF1R
      • Protein Name:
      • Insulin-like growth factor 1 receptor
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human IGF1R. AA range:1126-1175
      • Specificity:
      • IGF-IR Polyclonal Antibody detects endogenous levels of IGF-IR protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • IF 1:50-200 WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:10000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • IGF1R;Insulin-like growth factor 1 receptor;Insulin-like growth factor I receptor;IGF-I receptor;CD antigen CD221;INSR;Insulin receptor;IR;CD antigen CD220
      • Observed Band(KD):
      • pro: 155kD, recetor beta: 95kD
      • Background:
      • This receptor binds insulin-like growth factor with a high affinity. It has tyrosine kinase activity. The insulin-like growth factor I receptor plays a critical role in transformation events. Cleavage of the precursor generates alpha and beta subunits. It is highly overexpressed in most malignant tissues where it functions as an anti-apoptotic agent by enhancing cell survival. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. [provided by RefSeq, May 2014],
      • Function:
      • catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Defects in IGF1R may be a cause in some cases of resistance to insulin-like growth factor 1 (IGF1 resistance) [MIM:270450]. IGF1 resistance is a gowth deficiency disorder characterized by intrauterine growth retardation and poor postnatal growth accompanied with increased plasma IGF1.,enzyme regulation:Autophosphorylation activates the kinase activity.,function:This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade. When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low a
      • Subcellular Location:
      • Cell membrane ; Single-pass type I membrane protein .
      • Expression:
      • Found as a hybrid receptor with INSR in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts, spleen and placenta (at protein level). Expressed in a variety of tissues. Overexpressed in tumors, including melanomas, cancers of the colon, pancreas prostate and kidney.

      Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling. PLoS One Plos One. 2016 Mar;11(3):e0151857 WB Mouse 1:1000 kidney cortex tissues

      Negative Regulation of Grb10 Interacting GYF Protein 2 on Insulin-Like Growth Factor-1 Receptor Signaling Pathway Caused Diabetic Mice Cognitive Impairment. PLoS One 2014 Sep 30 WB Mouse 1∶1000 hippocampus

      Insulin-like growth factor II mRNA binding protein 3 regulates proliferation, invasion and migration of neuroendocrine cancer cells. International Journal of Clinical and Experimental Pathology Int J Clin Exp Patho. 2017; 10(10): 10269–10275 WB Mouse STC-1 cell

      Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms. Oncology Letters 2017 Feb 14 IHC Human 1:400 gastroenteropancreatic neuroendocrine neoplasm (GEP‑NEN)

      Marine bromophenol bis (2, 3-dibromo-4, 5-dihydroxybenzyl) ether, represses angiogenesis in HUVEC cells and in zebrafish embryos via inhibiting the VEGF signal systems." Biomedicine & Pharmacotherapy 75 (2015): 58-66.

      Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling. PLoS One Plos One. 2016 Mar;11(3):e0151857 WB Mouse 1:1000 kidney cortex tissues

      Amelioration of Diabetic Mouse Nephropathy by Catalpol Correlates with Down-Regulation of Grb10 Expression and Activation of Insulin-Like Growth Factor 1 / Insulin-Like Growth Factor 1 Receptor Signaling. PLoS One Plos One. 2016 Mar;11(3):e0151857 WB Mouse 1:1000 kidney cortex tissues

      Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY Qin Tingting IHC Human 1:800 lung adenocarcinoma tissue

      • Products Images
      • Xie, Jing, et al. "Negative regulation of Grb10 Interacting GYF Protein 2 on insulin-like growth factor-1 receptor signaling pathway caused diabetic mice cognitive impairment." PloS one 9.9 (2014): e108559.
      • Immunofluorescence analysis of rat-kidney tissue. 1,IGF-IR Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
      • Immunofluorescence analysis of rat-kidney tissue. 1,IGF-IR Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
      • Immunofluorescence analysis of mouse-lung tissue. 1,IGF-IR Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
      • Immunofluorescence analysis of mouse-lung tissue. 1,IGF-IR Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
      • Immunofluorescence analysis of mouse-kidney tissue. 1,IGF-IR Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
      • Immunofluorescence analysis of mouse-kidney tissue. 1,IGF-IR Polyclonal Antibody(red) was diluted at 1:200(4°C,overnight). 2, Cy3 labled Secondary antibody was diluted at 1:300(room temperature, 50min).3, Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B
      • Immunohistochemical analysis of paraffin-embedded Human-liver-cancer tissue. 1,IGF-IR Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.
      • Immunohistochemical analysis of paraffin-embedded Rat-kidney tissue. 1,IGF-IR Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.
      • Immunohistochemical analysis of paraffin-embedded Mouse-kidney tissue. 1,IGF-IR Polyclonal Antibody was diluted at 1:200(4°C,overnight). 2, Sodium citrate pH 6.0 was used for antibody retrieval(>98°C,20min). 3,Secondary antibody was diluted at 1:200(room tempeRature, 30min). Negative control was used by secondary antibody only.
      • Western Blot analysis of various cells using IGF-IR Polyclonal Antibody diluted at 1:2000
      • Western Blot analysis of Hela cells using IGF-IR Polyclonal Antibody diluted at 1:2000
      • Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue, using IGF1R Antibody. The picture on the right is blocked with the synthesized peptide.
      • Western blot analysis of lysates from 293 cells, treated with Insulin, using IGF1R Antibody. The lane on the right is blocked with the synthesized peptide.